EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeting Cytokine-Mediated Inflammation in Brain Disorders: Developing New Treatment Strategies

Rahul Mallick iD, Sanjay Basak iD, Premanjali Chowdhury, Prasenjit Bhowmik iD, Ranjit K Das iD, Antara Banerjee iD, Sujay Paul iD, Surajit Pathak iD, Asim K Duttaroy iD

Pharmaceuticals · 15.01.2025 · 18 (1) · 104

DOI: 10.3390/ph18010104 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 15.01.2025. Verfasst von Rahul Mallick und 8 weiteren Autor:innen. Beteiligte Einrichtung: A.I. Virtanen Institute for Molecular Sciences, Faculty of Health Sciences, University of Eastern Finland, 70211 Kuopio, Finland. Die Arbeit wurde bisher 100-mal zitiert (Crossref) und nennt 195 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Finnish Foundation for Cardiovascular Research, Finnish Cultural Foundation, Ida Montini Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cytokine-mediated inflammation is increasingly recognized for playing a vital role in the pathophysiology of a wide range of brain disorders, including neurodegenerative, psychiatric, and neurodevelopmental problems. Pro-inflammatory cytokines such as interleukin-1 (IL-1), tumor necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6) cause neuroinflammation, alter brain function, and accelerate disease development. Despite progress in understanding these pathways, effective medicines targeting brain inflammation are still limited. Traditional anti-inflammatory and immunomodulatory drugs are effective in peripheral inflammatory illnesses. Still, they face substantial hurdles when applied to the central nervous system (CNS), such as the blood–brain barrier (BBB) and unwanted systemic effects. This review highlights the developing treatment techniques for modifying cytokine-driven neuroinflammation, focusing on advances that selectively target critical cytokines involved in brain pathology. Novel approaches, including cytokine-specific inhibitors, antibody-based therapeutics, gene- and RNA-based interventions, and sophisticated drug delivery systems like nanoparticles, show promise with respect to lowering neuroinflammation with greater specificity and safety. Furthermore, developments in biomarker discoveries and neuroimaging techniques are improving our ability to monitor inflammatory responses, allowing for more accurate and personalized treatment regimens. Preclinical and clinical trial data demonstrate the therapeutic potential of these tailored techniques. However, significant challenges remain, such as improving delivery across the BBB and reducing off-target effects. As research advances, the creation of personalized, cytokine-centered therapeutics has the potential to alter the therapy landscape for brain illnesses, giving patients hope for better results and a higher quality of life.

Schlagwörter

Stichwörter der Autor:innen

biomarkers in neuroinflammationbrain disorders therapycytokine-mediated neuroinflammationpro-inflammatory cytokinestargeted drug delivery

Autor:innen und Institutionen

  • A.I. Virtanen Institute for Molecular Sciences, Faculty of Health Sciences, University of Eastern Finland, 70211 Kuopio, Finland.
  • Molecular Biology Division, ICMR-National Institute of Nutrition, Indian Council of Medical Research, Hyderabad 500007, India.
  • Institute of Public Health and Clinical Nutrition, School of Medicine, Faculty of Health Sciences, University of Eastern Finland, 70210 Kuopio, Finland.
  • Department of Chemistry, Uppsala Biomedical Centre, Uppsala University, SE-751 23 Uppsala, Sweden.
  • Department of Textile Engineering, Green University of Bangladesh, Narayanganj 1461, Bangladesh.
  • Department of Health and Biomedical Sciences, University of Texas Rio Grande Valley, Brownsville, TX 78520, USA.

ORCID-Profile: Rahul Mallick, Sanjay Basak, Prasenjit Bhowmik, Ranjit K Das, Antara Banerjee, Sujay Paul, Surajit Pathak, Asim K Duttaroy

Förderung

  • Finnish Foundation for Cardiovascular Research
  • Finnish Cultural Foundation
  • Ida Montini Foundation

Zitieren

APA

Mallick, R., Basak, S., Chowdhury, P., Bhowmik, P., Das, R. K., Banerjee, A., Paul, S., Pathak, S., & Duttaroy, A. K. (2025). Targeting Cytokine-Mediated Inflammation in Brain Disorders: Developing New Treatment Strategies. Pharmaceuticals, 18(1), 104. https://doi.org/10.3390/ph18010104

Vancouver

Mallick R, Basak S, Chowdhury P, Bhowmik P, Das RK, Banerjee A, et al. Targeting Cytokine-Mediated Inflammation in Brain Disorders: Developing New Treatment Strategies. Pharmaceuticals. 2025;18(1):104. doi:10.3390/ph18010104

BibTeX
@article{Mallick2025,
  author = {Mallick, Rahul and Basak, Sanjay and Chowdhury, Premanjali and Bhowmik, Prasenjit and Das, Ranjit K and Banerjee, Antara and Paul, Sujay and Pathak, Surajit and Duttaroy, Asim K},
  title = {Targeting Cytokine-Mediated Inflammation in Brain Disorders: Developing New Treatment Strategies},
  journal = {Pharmaceuticals},
  year = {2025},
  volume = {18},
  number = {1},
  pages = {104},
  doi = {10.3390/ph18010104}
}
Kostenlos starten →